M
Marc Bosiers
Publications - 114
Citations - 6163
Marc Bosiers is an academic researcher. The author has contributed to research in topics: Stent & Angioplasty. The author has an hindex of 34, co-authored 110 publications receiving 5463 citations.
Papers
More filters
Journal ArticleDOI
Nitinol Stent Implantation Versus Percutaneous Transluminal Angioplasty in Superficial Femoral Artery Lesions up to 10 cm in Length The Femoral Artery Stenting Trial (FAST)
Hans Krankenberg,Michael Schlüter,Hermann J. Steinkamp,Karlheinz Bürgelin,Dierk Scheinert,Karl-Ludwig Schulte,Erich Minar,Patrick Peeters,Marc Bosiers,Gunnar Tepe,Bernhard Reimers,Felix Mahler,Thilo Tübler,Thomas Zeller +13 more
TL;DR: The hypothesized absolute difference of 20% in binary restenosis at 1 year between the implantation of a single Luminexx nitinol stent and stand-alone PTA could not be demonstrated and no statistically significant difference between treatment groups was observed at 12 months in the improvement by at least 1 category of peripheral arterial disease.
Journal ArticleDOI
Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial.
Stephan H. Duda,Stephan H. Duda,Marc Bosiers,Johannes Lammer,Dierk Scheinert,Thomas Zeller,Vincent L. Oliva,Alexander V. Tielbeek,John Lennon Anderson,Benjamin Wiesinger,Gunnar Tepe,Alexandra J. Lansky,Michael R. Jaff,Catharina Mudde,Hans Tielemans,Jean-Paul Beregi +15 more
TL;DR: It is demonstrated that the sirolimus-eluting and the bare SMART stent are effective, safe, and free from restenosis in a majority of patients for up to 24 months.
Journal ArticleDOI
Sirolimus-Eluting versus Bare Nitinol Stent for Obstructive Superficial Femoral Artery Disease: The SIROCCO II Trial
Stephan H. Duda,Marc Bosiers,Johannes Lammer,Dierk Scheinert,Thomas Zeller,Alexander V. Tielbeek,John Lennon Anderson,Benjamin Wiesinger,Gunnar Tepe,Alexandra J. Lansky,Catharina Mudde,Hans Tielemans,Jean Paul Beregi +12 more
TL;DR: Although there is a trend for greater efficacy in the sirolimus-eluting stent group, there were no statistically significant differences in any of the variables.
Journal ArticleDOI
The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty
Dierk Scheinert,Stephan H. Duda,Thomas Zeller,Hans Krankenberg,Jens Ricke,Marc Bosiers,Gunnar Tepe,Scott Naisbitt,Kenneth Rosenfield +8 more
TL;DR: Treatment of femoropopliteal lesions with the low-dose Lutonix DCB reduced late lumen loss with safety comparable to that of control angioplasty with promising results with reduced restenosis.
Journal ArticleDOI
Drug-Eluting Balloon Versus Standard Balloon Angioplasty for Infrapopliteal Arterial Revascularization in Critical Limb Ischemia 12-Month Results From the IN.PACT DEEP Randomized Trial
Thomas Zeller,Iris Baumgartner,Dierk Scheinert,Marianne Brodmann,Marc Bosiers,Antonio Micari,Patrick Peeters,Frank Vermassen,Mario Landini,David Snead,K. Craig Kent,Krishna J. Rocha-Singh,In.Pact Deep Trial Investigators +12 more
TL;DR: In patients with CLI, IA-DEB had comparable efficacy to PTA and met the noninferiority hypothesis, but there was a trend towards an increased major amputation rate through 12 months compared to Pta.